VX-765: Selective Caspase-1 Inhibitor for Inflammatory Pathway Research

Executive Summary: VX-765 is a highly selective, orally bioavailable inhibitor of caspase-1, developed by APExBIO for advanced inflammation research (APExBIO). The compound is metabolized in vivo to VRT-043198, which directly inhibits caspase-1, leading to decreased secretion of interleukin-1β (IL-1β) and IL-18 without affecting TNFα, IL-6, or IL-8 (Israelov et al. 2020). VX-765 has demonstrated efficacy in murine models of arthritis, skin inflammation, and blood-brain barrier (BBB) injury. Its specificity enables the mechanistic dissection of inflammasome-driven pyroptosis in macrophages and CD4 T-cells. The compound's physicochemical properties and storage requirements facilitate its integration into diverse enzymatic and cellular workflows.

Biological Rationale

Caspase-1, also known as interleukin-1 converting enzyme (ICE), is a cysteine protease crucial for the maturation of pro-inflammatory cytokines IL-1β and IL-18. These cytokines are key mediators in the inflammatory cascade, contributing to disease states such as rheumatoid arthritis, neuroinflammation, and HIV-associated immune depletion (Israelov et al. 2020). Dysregulated caspase-1 activity drives pyroptosis, a lytic form of programmed cell death, especially in macrophages exposed to intracellular pathogens. Targeted inhibition of caspase-1 provides a route to modulate inflammatory responses while sparing other cytokine pathways, offering specificity not achieved with broader anti-inflammatory agents.

Mechanism of Action of VX-765

VX-765 is a pro-drug that is rapidly converted in vivo to its active metabolite, VRT-043198. The active form binds the catalytic site of caspase-1, blocking its proteolytic activation of pro-IL-1β and pro-IL-18. This inhibition effectively prevents the maturation and release of these cytokines from cells undergoing inflammasome activation. VX-765 displays minimal inhibition of other caspases (such as caspase-3, -8, or -9) and does not alter the levels of unrelated cytokines such as IL-6, IL-8, TNFα, or IL-α (APExBIO). This selectivity underpins its utility in studies dissecting caspase-1-specific pathways and their downstream effects.

Evidence & Benchmarks

• VX-765 restores blood-brain barrier integrity in vitro after paraoxon-induced injury, normalizing permeability and restoring VE-cadherin levels (Israelov et al. 2020, Fig. 5).
• In vivo, VX-765 administration to mice exposed to neurotoxic insult reduces endothelial adhesion molecule expression and transmigration of PBMCs (Israelov et al. 2020, Table 2).
• VX-765 inhibits IL-1β and IL-18 release in cell-based inflammasome activation assays at concentrations as low as 0.1–1 μM, with no effect on TNFα or IL-6 secretion (APExBIO).
• In collagen-induced arthritis mouse models, VX-765 significantly reduces joint inflammation and cytokine secretion compared to vehicle controls (APExBIO translational applications article).
• VX-765 prevents CD4+ T-cell pyroptotic death in HIV-infected lymphoid tissues in a dose-dependent manner (Biotin-Azide VX-765 review).

This article extends prior coverage such as APExBIO's translational immunology review by providing updated, in vivo benchmarks and detailed workflow guidance for experimentalists.

Applications, Limits & Misconceptions

VX-765 is used to dissect caspase-1-dependent inflammatory mechanisms in preclinical models of autoimmune, infectious, and neurodegenerative diseases. The compound is also under investigation for therapeutic potential in epilepsy and CNS disorders due to its ability to restore BBB function and limit neuroinflammation (Israelov et al. 2020). VX-765 is not a pan-caspase inhibitor and does not modulate caspase-3 or -8 activities, nor does it suppress non-caspase-1-dependent cytokine release. This specificity distinguishes it from broad-spectrum apoptosis inhibitors.

For further mechanistic exploration, see this analysis on mitochondrial cell death pathways; the current article focuses on validated inflammatory and BBB endpoints in primary human and murine systems.

Common Pitfalls or Misconceptions

• VX-765 does not inhibit other ICE-like proteases outside of caspase-1 under physiological conditions.
• It does not block apoptosis mediated by caspase-3, -8, or -9 (Israelov et al. 2020).
• It is ineffective against inflammasome-independent cytokine release (e.g., LPS-driven TNFα secretion).
• VX-765 is not water-soluble; improper dissolution may lead to precipitation and loss of activity. It should be dissolved in DMSO or ethanol at concentrations ≥313 mg/mL or ≥50.5 mg/mL, respectively (APExBIO).
• Long-term storage in solution is not recommended due to instability; freshly prepare working solutions for each experiment.

Workflow Integration & Parameters

VX-765 is supplied as a solid and should be stored desiccated at -20°C. For enzyme inhibition assays, dissolve in DMSO or ethanol and use at recommended concentrations. Standard protocols employ buffered conditions at pH 7.5, with additives such as 0.1% BSA to stabilize enzyme activity. For in vivo studies, oral or intraperitoneal administration is typical; dosing regimens should be validated in pilot studies. For short-term cell culture, final DMSO concentration should not exceed 0.1% (v/v). The A8238 kit from APExBIO provides validated purity and batch consistency for reproducible results.

This article also updates and clarifies cell death pathway integration from the Cy5-Azide VX-765 review by specifying experimental controls in primary BBB and arthritis models.

Conclusion & Outlook

VX-765 is a benchmark, selective caspase-1 inhibitor enabling precise modulation of inflammasome-driven cytokines and pyroptosis. Its application has clarified the pathophysiological role of caspase-1 in BBB injury, autoimmunity, and viral immunopathology. As the field advances, VX-765 and its active metabolite VRT-043198 are expected to inform both basic research and translational strategies for inflammatory disease intervention. For detailed protocols and specifications, refer to APExBIO's VX-765 product page.